CS-7017 + Erlotinib
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-Small-Cell Lung
Conditions
Carcinoma, Non-Small-Cell Lung
Trial Timeline
Jun 1, 2010 → Dec 1, 2011
NCT ID
NCT01199068About CS-7017 + Erlotinib
CS-7017 + Erlotinib is a phase 1 stage product being developed by Daiichi Sankyo for Carcinoma, Non-Small-Cell Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT01199068. Target conditions include Carcinoma, Non-Small-Cell Lung.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01199068 | Phase 1 | Completed |
| NCT01101334 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoma, Non-Small-Cell Lung